← LENZ Therapeutics, Inc. (LENZ) — catalysts, pipeline & price
Catalyst Dossier · compiled by CeliA 🧫
LENZ Therapeutics, Inc. (LENZ)
Biological Products, (No Diagnostic Substances) · market cap $122M
Research and calibrated estimates, not financial advice — verify before acting.
Next catalyst
2026-11-04 (est.)
Earnings
Pipeline
0
programs
Upcoming events
1
next 90d+
Dossier
Not yet
generate it
The catalyst path
- 2026-11-04 (est.)Earningsimp 5/10
Pipeline
No pipeline data.
Price & technical context
3-month
-35.0%
6-month
-62.4%
12-month
-92.6%
52-wk range
$3.64–$48.74
vs 50-day MA
-24.1%
vs 200-day MA
-61.0%
Realized vol
84.5%
Max drawdown
-92.6%
Daily closes through 2026-10-02. Realized vol annualized; max drawdown over ~2 years.
The full dossier is a Pro feature
Thesis, bull & bear, the if-approved scenario, financials, smart-money signals and risks — compiled by CeliA. The catalyst path & pipeline above are free.
Sources & data
- SEC filings — EDGAR filings for LENZ (10-K, 10-Q, S-3, 13D/G, Form 4)
- Market & financial data — SEC EDGAR (XBRL filings, Form 4), Yahoo Finance, Nasdaq — prices, statements, key metrics, insider & institutional filings.
- Regulatory — openFDA, FDA advisory & PDUFA calendars.
Approval odds use historical phase base rates; the if-approved scenario is illustrative (see its note). Figures trace to the sources above — verify before acting.
Data from CatalystAlert (ClinicalTrials.gov, SEC EDGAR, openFDA, market-data providers). Compiled by CeliA. Not financial advice.